Boston Scientific Exceeds Wall Street’s Expectations In Q3
Executive Summary
Boston Scientific’s management believes the ongoing recovery of procedure volumes and new technology will allow it to show revenue growth in the fourth quarter.
You may also be interested in...
Boston Scientific Is Counting On COVID-19 Vaccine To Rebound In 2021
The company expects revenues across its businesses to rapidly return to their pre-pandemic growth rates in the second half of 2021.
JPM 2021: Boston Scientific, Abbott, Dexcom, Insulet, Silk Road Medical
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the second day of the meeting.
Boston Scientific Gives Up On Lotus Edge TAVR
The company is recalling all unused Lotus Edge inventory and will stop developing the Lotus platform while shifting resources to support its Acurate neo2 transcatheter aortic valve system. The decision will cost the company up to $300m.